Rubella Vaccine

Core Characteristics

Live-attenuated viral vaccine.
Derived from Wistar RA 27/3 vaccine strain.
Grown in human diploid or chick embryo cell cultures.
Formulated commonly as combination Measles-Rubella or Measles-Mumps-Rubella vaccine.

Parameter	Specification
Dose volume	0.5 mL
Route	Subcutaneous
Anatomical site	Right upper arm (deltoid insertion) or anterolateral thigh

Available in freeze-dried (lyophilized) form.
Requires reconstitution with sterile diluent prior to use.
Store frozen or at 2°C to 8°C.
Highly sensitive to heat and light.
Protect reconstituted vaccine from light.
Discard unused reconstituted vaccine within 4 to 6 hours to prevent toxic shock syndrome.

Single dose provides lifelong protection in over 95% of vaccinees.
Primary goal prevents Congenital Rubella Syndrome.
Suboptimal coverage shifts disease epidemiology to older age groups, paradoxically increasing Congenital Rubella Syndrome incidence.
Maternal antibodies interfere with vaccine response before 9 months.

Mild rash develops in 5% of vaccinees.
Joint symptoms including arthralgia and arthritis occur 1 to 3 weeks post-vaccination.
Joint symptoms predominantly affect susceptible post-pubertal females.
Immune thrombocytopenic purpura occurs at frequency of 1 per 30,000 vaccinations.
Chronic arthritis lasting less than 6 weeks constitutes notable serious adverse event.

Strictly contraindicated in severely immunocompromised states, including high-dose corticosteroid therapy exceeding 14 days and severe human immunodeficiency virus.
Contraindicated during pregnancy.
Avoid pregnancy for 4 weeks following vaccination.
Accidental vaccination during pregnancy does not increase risk of congenital malformations.
Accidental vaccination in pregnancy does not warrant medical termination.
Delay vaccination 3 to 11 months following administration of antibody-containing blood products.
Routine pregnancy testing prior to immunization remains unnecessary.